Prognostic Value of ERM Gene Expression in Human Primary Breast Cancers

• Published in: Clinical cancer research 2004-11, Vol.10 (21), p.7297-7303
• Main Authors: Chotteau-Lelièvre, Anne, Révillion, Françoise, Lhotellier, Valérie, Hornez, Louis, Desbiens, Xavier, Cabaret, Véronique, de Launoit, Yvan, Peyrat, Jean-Philippe
• Format: Article
• Language: English
• Subjects: Adult; Antineoplastic agents; Biological and medical sciences; Breast Neoplasms - diagnosis; Breast Neoplasms - metabolism; Cell Line, Tumor; Disease-Free Survival; DNA Primers - chemistry; DNA-Binding Proteins - biosynthesis; DNA-Binding Proteins - genetics; DNA-Binding Proteins - physiology; Female; Humans; Lymphatic Metastasis; Medical sciences; Middle Aged; Multivariate Analysis; Pharmacology. Drug treatments; Prognosis; Proportional Hazards Models; Receptor, Epidermal Growth Factor - biosynthesis; Receptor, Epidermal Growth Factor - metabolism; Receptor, ErbB-4; Receptors, Estradiol - biosynthesis; Receptors, Estradiol - metabolism; Receptors, Progesterone - biosynthesis; Receptors, Progesterone - metabolism; Reverse Transcriptase Polymerase Chain Reaction; Risk; RNA - metabolism; RNA, Messenger - metabolism; Time Factors; Transcription Factors - biosynthesis; Transcription Factors - genetics; Transcription Factors - physiology; Tumors
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-04-0593

We measured the expression of ERM gene, a nuclear transcription factor belonging to the ets family, in a series of 364 unselected primary breast cancers from patients who underwent locoregional surgery in the Centre Oscar Lambret between May 1989 and December 1991. The expression of ERM was quantified with a real-time one-step reverse transcription-PCR assay based on the 5′-nuclease activity of the TaqDNA polymerase and with an Abi Prism 7700 Sequence Detector System (Applied Biosystems, Courtaboeuf, France). ERM was positively correlated (Spearman test) to epidermal growth factor receptor (EGFR; P < 0.001, r = 0.296) and to histoprognostic grading ( P = 0.044, r = 0.112), whereas it was negatively correlated to estradiol receptors ( P = 0.019, r = -0.124), HER3 (c-erbB-3; P = 0.01, r = −0.135), and HER4 (c-erbB-4; P = 0.003, r = −0.154). Using the χ 2 test, a positive relationship was found between the expression of ERM and EGFR (χ 2 = 7.795, P = 0.007). In overall survival studies, Cox univariate analyses demonstrated a prognostic value of ERM ( P = 0.006; risk ratio, 2.95) besides the classical prognostic factors histoprognostic grading, node involvement, tumor size, estradiol receptors, progesterone receptors, EGFR, HER3, and HER4. In multivariate analyses, ERM preserved its prognostic value ( P = 0.004; risk ratio, 3.779) together with histoprognostic grading, tumor size, estradiol receptors, and progesterone receptors. In relapse-free survival studies, univariate analyses demonstrated that histoprognostic grading, node involvement, tumor size, and HER4 were prognostic factors. These parameters, except histoprognostic grading, retained their prognostic value in multivariate analyses. This study demonstrates for the first time that ERM gene expression is an independent adverse prognostic factor for overall survival in breast cancer patients.